EUCTR2012-003499-37-DE进行中（未招募）1 期
ong-term Study Evaluating the Effect of givinostat in Patients With JAK2V617F positive Chronic Myeloproliferative Neoplasms
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must have completed Givinostat treatment on at least one core study in cMPN (i.e. Study DSC/07/2357/28, DSC/08/2357/38 and/ or any future core protocols in cMPN), or Patients must be participating in a compassionate use program with Givinostat and Patients must have tolerated previous Givinostat treatment and achieved a clinical benefit at the end of core protocols or compassionate use program with Givinostat, assessed by the Investigator according to the revised clinico-haematological ELN response criteria (for PV and ET) and EUMNET response criteria (for MF)
- •2. Patients must be able to provide informed consent and be willing to sign an informed consent form
- •3. Adult patients (age =18 years), of both genders, and with established diagnosis of JAK2V617F positive cMPN according to the revised WHO criteria
- •4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status <3 at baseline
- •5. Acceptable organ function within 7 days of initiating study drug
- •6. Use of an effective means of contraception from the 28 days before first dose of study drug through 3 months after the last dose of study drug for women of childbearing potential and men with partners of childbearing potential
- •7. Willingness and capability to comply with the requirements of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1. Pregnancy or nursing (lactating) women, where pregnancy is defined as the state of a female after conception, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test (i.e. >5 mIU/mL) an until the termination of gestation;
- •2. A clinically significant QTc prolongation at baseline (e.g. repeated demonstration of a QTc interval = 450 msec); Of note, a repeated demonstration of a QTc interval >450 msec means that, if the first ECG evaluation demonstrates a prolonged QTc interval (i.e. a QTc interval = 450 msec), two additional ECG evaluations over a brief period of time (i.e. 5 minutes between each recording) must be performed. The averaged value of these three ECG evaluations has to be used for the evaluation of the QTc interval. In the eCRF all the performed ECG evaluations have to be entered as well as the average value of multiple ECG evaluation, if necessary
- •3. Use of drugs concomitant medications known to prolong the QTc interval
- •4. Clinically significant cardiovascular disease including:
- •- Uncontrolled hypertension, myocardial infarction, unstable angina within 6 months of study start;
- •- New York Heart Association (NYHA) grade II or greater congestive heart failure
- •- History of any cardiac arrhythmia requiring medication (regardless of severity)
- •- A history of additional risk factors for TdP (eg, heart failure, hypokalemia, family history of long QTc syndrome)
- •5. Active virus infection including HIV, HBV and HCV
- •6. Platelets count <100 x109/L within 14 days before enrolment
- •7. Absolute neutrophil count < 1.2 x109/L within 14 days before enrolment
- •8. Total serum bilirubin >1.5xULN except in case of Gilbert's disease or pattern consistent with Gilbert's disease
- •9. Serum asparatate aminotransferase / alanine aminotransferase AST/ALT >3xULN
- •10. Serum Cystatin C > 2 x ULN for two subsequent evaluations (i.e. if the value of serum Cystatin C is > 2 x ULN, the test will be repeated once, and if the value is again > 2 x ULN, this becomes an exclusion criterion).
- •11. Uncontrolled hypertriglyceridemia at baseline, i.e. triglycerides >1.5xULN in fasting state.
- •12. History and/or presence of other diseases, metabolic dysfunctions, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicated use of an investigational drug or that might affect interpretation of the results of the study or might render the patient at high risk from treatment complications or significantly alter the absorption of the study drug
- •13. Any investigational drug other than givinostat within 28 days before enrolment. Notably . the use of such medicaitons within 28 days or 6 half-lives - whichever is longer - prior to the first dose of study drugs (i.e. Day 1) and during the study through all the study conduct (including any safety follow-up [FU] visit) is prohibited.
- •14. Use of concomitant medications known to inhibit Pgp
- •15. Patients with known hypersensitivity to the components of potential study therapy
研究者
相似试验
进行中（未招募）
1 期
ong-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsChronic myeloproliferative neoplasmMedDRA version: 19.0Level: HLTClassification code 10028578Term: Myeloproliferative disorders (excl leukaemias)System Organ Class: 100000004851EUCTR2012-003499-37-PLITALFARMACO S.p.A90
进行中（未招募）
不适用
ong-term study evaluating the effect of Givinostat in cMPN.Chronic myeloproliferative neoplasms (cMPN).MedDRA version: 14.1Level: HLTClassification code 10028578Term: Myeloproliferative disorders (excl leukaemias)System Organ Class: 100000004851EUCTR2012-003499-37-ITITALFARMACO
招募中
1 期
ong-term study evaluating the effect of givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasmsChronic myeloproliferative neoplasmMedDRA version: 20.0Level: HLTClassification code: 10028578Term: Myeloproliferative disorders (excl leukaemias) Class: 10029104CTIS2024-512413-40-00Italfarmaco S.p.A.53
尚未招募
2 期
A clinical trial to study the effectiveness of gavakshi moola decoction with milk in kamala (hepatocellular jaundice).CTRI/2018/08/015390Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital hassan
尚未招募
2 期
clinical study on the effect of Gudapippali Ghruta and Shatavari Ghruta in the management of Parinama shoola(Acid Peptic Disorders ) and to study the role of H.Pylori in its manifastation.â??CTRI/2017/08/009316Rajiv Gandhi University of Health Sciences